ExBRAC- Expressive Writing in Breast Cancer

Expressive Writing in Breast Cancer - The ExBRAC Trial

Status

Enrolling by invitation

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07298980

Acronym

ExBRAC

Enrollment

272

Registered

2025-12-23

Start date

2026-02-01

Completion date

2029-12-31

Last updated

2026-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

breast cancer, quality of life, expressive writing

Brief summary

The study is a randomized trial designed to examine whether an "expressive writing" intervention can affect the quality of life in patients recently diagnosed with breast cancer. The method "expressive writing" consists of writing about the breast cancer or other related subjects during 20 minutes, once a week for four consecutive weeks. The impact on quality of life will be assessed by having participants complete questionnaires at three different time points during the study. The questionnaire will be developed using a clinimetric approach, based on semi-structured interviews with breast cancer patients. The themes emerging from these interviews will be used to formulate the questions. Additionally, well-known quality-of-life measurement instruments and registry data with clinically relevant information-such as tumor stage and treatment-will be incorporated.

Interventions

BEHAVIORALExpressive Writing

Expressive writing means that the patient writes privately about the cancer or other related subject for 20 minutes. This will be repeated once a week for 4 weeks. The writing should be done in a place free from distractions and on the patients' mother tongue. The text will not be collected.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Planned for surgery of breast cancer without neoadjuvant treatment

Exclusion criteria

* Not able to understand Swedish * Previous breast cancer

Design outcomes

Primary

Measure	Time frame	Description
Health-related quality of life	At the 12 months follow-up	According to EQ-5D-5L VAS. The scale ranges from 0-100 where 0 is "worst possible health" and 100 is "best possible health".

Countries

Sweden

Contacts

PRINCIPAL_INVESTIGATORLinnea Huss, M.D., Ph.D.

Lund University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 14, 2026